Subject(s)
Streptococcal Infections/drug therapy , Streptococcus pyogenes/isolation & purification , Tonsillitis/drug therapy , Adult , Child , Diagnosis, Differential , Dose-Response Relationship, Drug , Hemolysis/drug effects , Humans , Microbial Sensitivity Tests , Recurrence , Streptococcal Infections/diagnosis , Tonsillitis/diagnosis , Tonsillitis/microbiologyABSTRACT
An open non-comparative study of rovamycin (spiramycin produced by Rhone-Poulenc Rorer) for intravenous administration was performed to evaluate its clinical and bacteriological efficacy, safety and tolerance. Thirty patients (adults aged 16-65 years) with community-acquired pneumonia were involved into the study. Two patients were dropped out because of adverse events. Dosage regimen was 1,500,000 I.U. three times a day (intravenous infusion). The treatment was continued after partial recovery (3,000,000 I.U. per os). Spiramycin showed a high clinical efficacy. Approximately half of the patients (41.4-55.6%) had positive clinical trends by third day of spiramycin treatment. The overall clinical efficacy by the completion of the drug administration reached 90.0%. Bacteriological activity was observed in 93.4% of the patients treated. Adverse events were observed in 6 (20.0%) patients, including 2 dropouts. Serious side effects were not registered. As rovamycin showed high clinical efficacy and good safety the drug may be recommended for the treatment of adult pneumonia.
Subject(s)
Pneumonia/drug therapy , Spiramycin/administration & dosage , Acute Disease , Adolescent , Adult , Aged , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Erythromycin/administration & dosage , Humans , Infusions, Intravenous , Middle Aged , Pneumonia/diagnosis , Pneumonia/microbiology , Spiramycin/adverse effects , Tablets , Time FactorsABSTRACT
Spiramycin activity against acute pneumonia has been studied in 21 outpatients (15 adults and 6 children). The drug was administered orally twice daily in a dose 3,000,000 units. The course lasted from 7 to 14 days. All the cases were confirmed roentgenologically. The disease ran a moderate-severity course. The response rate reached 95.2%. Another course of antibiotic therapy was not needed. Side effects were not registered. Bacteriological efficacy of spiramycin made up 71.3%. 14 out of 16 isolated strains of causative agents (S.pneumoniae, S.pyogenes, S.aureus, H.influenzae in 5, 1, 7 and 3 patients, respectively) proved sensitive to spiramycin. 2 patients developed mycoplasma infection diagnosed serologically. The findings confirm high therapeutic efficacy of spiramycin, its good tolerance. Spiramycin may be considered the drug of the priority choice in outpatient treatment of acute pneumonia.
Subject(s)
Pneumonia/drug therapy , Spiramycin/administration & dosage , Administration, Oral , Adolescent , Adult , Child , Drug Resistance, Microbial , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Humans , Middle Aged , Outpatients , Pneumonia/microbiology , Spiramycin/pharmacology , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification , Streptococcus pyogenes/drug effects , Streptococcus pyogenes/isolation & purification , Time FactorsABSTRACT
The use of correlations between the pharmacokinetic parameters and the patient's factors is one of the most promising trends in the elaboration of the efficient regimens of dosage. To establish the analogous correlations in terms of specifying the causes of the widely known individual variability of serum aminoglycoside concentrations in 139 neonates given amikacin for suggested or documented infections, a study was made of the drug pharmacokinetics.
